New Zealand - English - Medsafe (Medicines Safety Authority)

orpharma nz limited - sodium phenylbutyrate 84 g equivalent to 483 mg of sodium phenylbutyrate per gram of granules;  ;   - oral granules - 483 mg - active: sodium phenylbutyrate 84 g equivalent to 483 mg of sodium phenylbutyrate per gram of granules     excipient: ethylcellulose hypromellose macrogol 1500 povidone sugar spheres - pheburane is indicated as adjunctive therapy in the chronic management of urea cycle disorders, involving deficiencies of carbamylphosphate synthetase, ornithine transcarbamylase or argininosuccinate synthetase. pheburane should be used with dietary protein restriction and, in some cases, dietary supplements (e.g., essential amino acids, arginine, citrulline, and protein-free calorie supplements). pheburane is indicated in all patients with neonatal-onset presentation (complete enzyme deficiencies, presenting within the first 28 days of life). it is also indicated in patients with late-onset disease (partial enzyme deficiencies, presenting after the first month of life) who have a history of hyperammonaemic encephalopathy. geriatrics (> 65 years of age): pheburane has not been studied in the geriatric population.

New Zealand - English - Medsafe (Medicines Safety Authority)

phebra nz limited - monobasic sodium phosphate 1.936 g equivalent to to 500 mg phosphorus - effervescent tablet - 500 mg - active: monobasic sodium phosphate 1.936 g equivalent to to 500 mg phosphorus excipient: citric acid confectioner's sugar macrogol 4000 orange concentrate firmenich potassium bicarbonate saccharin sodium sodium bicarbonate - treatment of high blood calcium caused by overactive parathyroid glands or a cancer of the blood (multiple myelomatosis) and other cancers.

Australia - English - Department of Health (Therapeutic Goods Administration)

phebra pty ltd - colistimethate sodium, quantity: 1 million iu - inhalation - excipient ingredients: - colistimixin phebra powder for nebuliser solution is indicated for the treatment of colonisation and infections of the lung due to susceptible pseudomonas aeruginosa in patients with cystic fibrosis. consideration should be given to official guidance on the appropriate use of antibacterial agents.

Canada - English - Health Canada

medunik canada - sodium phenylbutyrate - granules - 483mg - sodium phenylbutyrate 483mg

New Zealand - English - Medsafe (Medicines Safety Authority)

phebra nz limited - metaraminol tartrate 18.96 mg/ml equivalent to metaraminol 10 mg - solution for injection - 10 mg/ml - active: metaraminol tartrate 18.96 mg/ml equivalent to metaraminol 10 mg excipient: sodium chloride sodium hydroxide sodium metabisulfite tartaric acid water for injection - prevention and treatment of the acute hypotensive state occurring with spinal anaesthesia; adjunctive treatment of hypotension due to haemorrhage, reactions to medications, surgical complications, and shock associated with brain damage due to tumour or trauma.

New Zealand - English - Medsafe (Medicines Safety Authority)

phebra nz limited - metaraminol tartrate 0.95 mg/ml equivalent to metaraminol 0.5 mg/ml - solution for injection - 3 mg/6ml - active: metaraminol tartrate 0.95 mg/ml equivalent to metaraminol 0.5 mg/ml excipient: sodium chloride sodium hydroxide sodium metabisulfite tartaric acid water for injection - prevention and treatment of the acute hypotensive state occurring with spinal anaesthesia; adjunctive treatment of hypotension due to haemorrhage, reactions to medications, surgical complications, and shock associated with brain damage due to tumour or trauma.

New Zealand - English - Medsafe (Medicines Safety Authority)

phebra nz limited - metaraminol tartrate 0.95 mg/ml equivalent to metaraminol 0.5 mg/ml - solution for injection - 5 mg/10ml - active: metaraminol tartrate 0.95 mg/ml equivalent to metaraminol 0.5 mg/ml excipient: sodium chloride sodium hydroxide sodium metabisulfite tartaric acid water for injection - prevention and treatment of the acute hypotensive state occurring with spinal anaesthesia; adjunctive treatment of hypotension due to haemorrhage, reactions to medications, surgical complications, and shock associated with brain damage due to tumour or trauma.

Australia - English - Department of Health (Therapeutic Goods Administration)

phebra pty ltd - sulthiame, quantity: 200 mg - tablet, film coated - excipient ingredients: purified talc; macrogol 4000; maize starch; lactose monohydrate; titanium dioxide; gelatin; hypromellose; colloidal anhydrous silica; magnesium stearate - indications as at 01 january 1991 : behavioural disorders associated with epilepsy; hyperkinetic behaviour; temporal lobe epilepsy; myoclonic seizures; grand mal attacks; jacksonian seizures.

Australia - English - Department of Health (Therapeutic Goods Administration)

phebra pty ltd - sulthiame, quantity: 50 mg - tablet, film coated - excipient ingredients: hypromellose; titanium dioxide; macrogol 4000; purified talc; gelatin; lactose monohydrate; magnesium stearate; maize starch; colloidal anhydrous silica - indications as at 01 january 1991 : behavioural disorders associated with epilepsy; hyperkinetic behaviour; temporal lobe epilepsy; myoclonic seizures; grand mal attacks; jacksonian seizures.

Australia - English - Department of Health (Therapeutic Goods Administration)

phebra pty ltd - phenol, quantity: 250 mg - injection, solution - excipient ingredients: almond oil - haemorol is indicated for the treatment of symptomatic haemorrhoids in patients with an inadequate response to conservative therapy such as dietary manipulation. it must only be injected submucosally and its use is usually confined to first degree or second degree haemorrhoids.